 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Jane E. Ambler, Ph.D. has been appointed as Vice President of Clinical Microbiology. Dr. Ambler will lead the the Companys microbiology efforts in support of the pivotal Phase 3 DISRUPT Direct Lysis of Staph aureus Resistant Pathogen Trial superiority study of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis and in advancement of the Companys pipeline of DLAs. Dr. Ambler has over 25 years of experience in clinical laboratory microbiology and antimicrobial drug development, and she has numerous book and journal publications. 